Bradley Foster & Sargent Inc. CT Buys 2,563 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bradley Foster & Sargent Inc. CT boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 17.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,842 shares of the medical research company’s stock after purchasing an additional 2,563 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Edwards Lifesciences were worth $1,556,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Crewe Advisors LLC bought a new stake in Edwards Lifesciences in the 1st quarter worth approximately $28,000. First Community Trust NA bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $29,000. Riverview Trust Co bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $34,000. DSM Capital Partners LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Finally, Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $39,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.4 %

Shares of EW stock opened at $67.53 on Thursday. The stock has a market cap of $40.69 billion, a P/E ratio of 29.11, a PEG ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $70.89 and its two-hundred day simple moving average is $83.11.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 EPS. Analysts predict that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on EW. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a research report on Thursday, July 25th. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $85.00 to $70.00 in a research report on Wednesday. Baird R W downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. UBS Group cut their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Finally, Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $79.82.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,378,659.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,250 shares of company stock worth $1,218,138. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.